Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sexual supplement recall

This article was originally published in The Tan Sheet

Executive Summary

In its latest warning on adulterated supplements sold as treatments for erectile dysfunction, FDA advises consumers not to use Blue Steel or Hero products distributed by Active Nutraceuticals because they are considered unapproved drugs and have not been proven to be safe or effective. The products contain undeclared and unapproved substances similar in chemical structure to sildenafil (Pfizer's Viagra), FDA says. "Because these products are labeled as 'all natural dietary supplements,' consumers may assume that they are harmless and pose no health risk," but the sildenafil may interact with nitrates found in some prescription drugs and can lower blood pressure to dangerous levels, the agency says (1"The Tan Sheet" Jan. 28, 2008, p. 11). Active, a unit of Carrollton, Ga.-based Marion Group, distributes Blue Steel in 10-count bottles or in blister packs and Hero in two-capsule blister packs...

You may also be interested in...

FDA Action On Sexual Supplements Should Spur Better Self-Policing – UNPA

The proliferation of erectile dysfunction "dietary supplements" adulterated with prescription drugs should lead the supplement industry to sharpen its capabilities to keep these illegal products off the market, United Natural Products Alliance President Loren Israelsen says

EU Nitrosamines Oversight Group Identifies Priority Topics

After agreeing on an EU-wide harmonized approach to deal with nitrosamine contamination in medicines, a newly-created regulatory oversight group has identified several topics requiring further scientific discussion.

Lilly Takes Another Leap Into Gene Therapy With Jaguar

Following last year's licensing deal with Precision Biosciences and the acquisition of Prevail Therapeutics, Eli Lilly is expanding its gene therapy efforts by backing Jaguar, a start-up staffed by former AveXis bosses.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts